drugset / Trial / NCT00267514

Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients

NCT00267514

Phase 3 Completed 31 enrolled Genzyme, a Sanofi Company
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine if sevelamer carbonate powder is an effective treatment for the control of serum phosphorous levels in patients on dialysis when compared to sevelamer hydrochloride tablets.

Timeline

Start
2006-01
Primary completion
2007-03
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sevelamer Other / unclassified